Anti-GTPase HRAS antibody [Y132] (ab32417)
- Product nameAnti-GTPase HRAS antibody [Y132]See all GTPase HRAS primary antibodies ...
- DescriptionRabbit monoclonal [Y132] to GTPase HRAS
- SpecificityReactivity with other RAS members has not, to our knowledge, been tested.
- Tested applicationsWB, ICC/IF, IP, Flow Cyt more details
- Species reactivityReacts with: Mouse, Rat, Human
Predicted to work with: Chicken
A synthetic peptide corresponding to residues in the C-terminus of human H-Ras.
- Positive control
- MCF7 and PC12 cell lysates and MCF7 cells.
- General notesProduced under U.S. Patent No. 5,675,063.
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferPBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05%
- Concentration information loading...
- PurityProtein A purified
- Clonality Monoclonal
- Clone numberY132
Our Abpromise guarantee covers the use of ab32417 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||WB: 1/500. Detects a band of approximately 21 kDa.|
|ICC/IF||ICC/IF: 1/100 - 1/250.|
|Flow Cyt||Flow Cyt: 1/100.|
- FunctionRas proteins bind GDP/GTP and possess intrinsic GTPase activity.
- Involvement in diseaseDefects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
- Sequence similaritiesBelongs to the small GTPase superfamily. Ras family.
modificationsPalmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
- Cellular localizationCell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
- c bas/has antibody
- c H ras antibody
- C HA RAS1 antibody
- c has/bas p21 protein antibody
- c ras Ki 2 activated oncogene antibody
- c ras Ki 2 protein antibody
- c-H-ras antibody
- CTLO antibody
- G1III6 N ras antibody
- GTP and GDP binding peptide B antibody
- GTPase HRas antibody
- GTPase HRas, N-terminally processed antibody
- H Ras 1 antibody
- H ras oncogene antibody
- H RasIDX antibody
- H-Ras-1 antibody
- Ha Ras antibody
- Ha Ras1 proto oncoprotein antibody
- Ha-Ras antibody
- HAMSV antibody
- HRAS 1 antibody
- HRAS antibody
- HRAS1 antibody
- K ras antibody
- N ras antibody
- p19 H RasIDX protein antibody
- p21 protein antibody
- p21ras antibody
- Ras family small GTP binding protein H Ras antibody
- RASH 1 antibody
- RASH_HUMAN antibody
- RASH1 antibody
- Transformation gene oncogene HAMSV antibody
- Transforming protein p21 antibody
- v Ha RAS antibody
- v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
- VH Ras antibody
- vHa RAS antibody
Anti-GTPase HRAS antibody [Y132] images
Overlay histogram showing HeLa cells stained with ab32417 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab32417, 1/100 dilution) for 30 min at 22°C. The secondary antibody used was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) (ab150077) at 1/2000 dilution for 30 min at 22°C. Isotype control antibody (black line) was rabbit IgG (monoclonal) (1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter.
All lanes : Anti-GTPase HRAS antibody [Y132] (ab32417) at 1/500 dilution
Lane 1 : MCF7 cell lysate
Lane 2 : PC12 cell lysate
Observed band size : 21 kDa (why is the actual band size different from the predicted?)
Immunohistochemical staining of MCF7 cells using ab32417 at 1/100 dilution.
References for Anti-GTPase HRAS antibody [Y132] (ab32417)
This product has been referenced in:
- Haeussler DJ et al. Endomembrane H-Ras controls vascular endothelial growth factor-induced nitric-oxide synthase-mediated endothelial cell migration. J Biol Chem 288:15380-9 (2013). WB ; Human . Read more (PubMed: 23548900) »
- Lau R et al. cIAP2 represses IKKa/ß-mediated activation of MDM2 to prevent p53 degradation. Cell Cycle 11:4009-19 (2012). Read more (PubMed: 23032264) »